Introduction

The forests of Central Africa, particularly those of Gabon, which cover nearly 88% of the national territory, contain hundreds of plants with recognized medicinal properties. Yet local populations still derive very little value from these resources. Foreign laboratories exploit both these biological resources and traditional knowledge to develop highly profitable patented medicines, often without fair benefit sharing. This phenomenon, widely known as biopiracy, raises major economic, scientific, and ethical concerns. Understanding its mechanisms is therefore essential to designing solutions capable of reversing this trend.

Biopiracy: When Ancestral Knowledge Becomes a Foreign Patent

The process is simple. A foreign researcher approaches a Gabonese traditional healer, documents the medicinal use of a plant, isolates its active compound, and files an international patent. Once protected abroad, the country of origin has little or no legal recourse. A clear example is Prunus africana. Its bark, harvested in Gabon, is exported raw to Europe, where it is transformed into patented medicines whose market value increases exponentially. Meanwhile, Gabon receives only a tiny fraction of the profits. Similar cases remain poorly documented in Central Africa, not because they are rare, but because institutional monitoring capacities remain insufficient.

A Protocol Without Enforcement: The Silent Cost of Legal Inaction

The Nagoya Protocol requires users of genetic resources to obtain prior consent from countries of origin and ensure fair and inclusive benefit sharing. Gabon has ratified the protocol, yet no effective national mechanism currently exists to enforce it. There is no operational one stop system, protected database, or effective permit structure. As a result, foreign researchers continue to access Gabonese forests through opaque collaborations. Every passing year represents a significant economic loss for Gabon. This loss is reflected in the absence of genuine local processing of biological resources, the chronic weakness of national research institutions such as IPHAMETRA, the inadequacy of legal frameworks capable of regulating access to genetic resources and guaranteeing equitable benefit sharing, and the lack of a long-term strategic vision.

How Can Gabon Position Itself? Four Strategic Priorities

First, Gabon must sovereignly document its medicinal biodiversity through a protected national database. Second, the country must strengthen local scientific capacity by equipping IPHAMETRA with chromatography and mass spectrometry technologies capable of characterizing active compounds before any external disclosure. Third, the Nagoya framework must be fully operational through a national authority dedicated to access and benefit sharing, empowered to negotiate clauses on revenue sharing from patents. Fourth, Gabon should develop local standardized extraction industries. Transforming raw bark into certified extracts dramatically increases economic value. For private entrepreneurs, this is where recoverable wealth truly lies.

Conclusion

Gabon’s forest quietly heals the world without receiving compensation proportional to its contribution. This situation is not inevitable. It is the consequence of insufficient strategy and political will, both of which can be corrected. Acting now would allow Gabon to become a major player in the global pharmaceutical industry, not merely a supplier of raw materials, but a sovereign producer of high value medicinal extracts.

Social Media: https://www.linkedin.com/in/merveil-agbovi-a85707220/